Table 1 Clinical characteristics of 21 patients who received intravitreal ziv-aflibercept injections for dense vitreous hemorrhage secondary to refractory proliferative diabetic retinopathy with previous panretinal photocoagulation
From: Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
Number | Age | Gender | OD or OS | Initial vision | Final vision | Number of injections | Follow-up (months) | Interval between injections (months) | Mean time for recovery (weeks) |
|---|---|---|---|---|---|---|---|---|---|
1 | 75 | F | OS | 20/200 | 20/200 | 4 | 9 | 5;1;2 | 6 |
2 | 65 | M | OD | HM | 20/400 | 1 | 3 | – | 4 |
3 | 31 | F | OD | 20/400 | 20/80 | 1 | 2 | – | 4 |
4 | 31 | F | OS | 20/125 | 20/125 | 1 | 3 | – | 8 |
5 | 65 | F | OS | 20/125 | 20/50 | 2 | 6 | 1 | 12 |
6 | 60 | F | OS | 20/200 | 20/200 | 1 | 2 | – | 4 |
7 | 52 | F | OD | 20/100 | 20/30 | 2 | 4 | 1 | 12 |
8 | 55 | M | OD | 20/2000 | 20/20 | 1 | 2 | – | 4 |
9 | 51 | M | OS | CF2m | 20/300 | 1 | 1 | – | 2 |
10 | 64 | F | OS | CF2m | 20/100 | 2 | 27 | 27 | 2 |
11 | 56 | M | OD | CF4m | 20/50 | 3 | 3 | 1 | 4 |
12 | 52 | M | OD | HM | 20/30 | 6 | 34 | 10;3;3;10;6 | 6 |
13 | 52 | M | OS | CF3m | 20/60 | 5 | 32 | 10;7;10;6 | 8 |
14 | 57 | M | OS | 20/80 | 20/50 | 5 | 18 | 1;3;5;10 | 2 |
15 | 57 | M | OD | 20/100 | 20/50 | 2 | 8 | 2 | 6 |
16 | 64 | M | OD | 20/100 | 20/50 | 1 | 8 | – | 1 |
17 | 33 | F | OD | HM | 20/150 | 5 | 33 | 12;3;12;12;7 | 8 |
18 | 33 | F | OS | 20/200 | 20/50 | 1 | 12 | – | NA |
19 | 74 | M | OS | CF1m | 20/50 | 3 | 20 | 7;11 | 2 |
20 | 73 | M | OD | CF2m | 20/25 | 2 | 3 | 3 | 5 |
21 | 73 | M | OS | HM | 20/40 | 2 | 2 | 1.3 | 7 |
22 | 66 | F | OD | 20/200 | 20/60 | 1 | 19 | – | 8 |
23 | 66 | F | OS | CF1m | CF3m | 5 | 30 | 8;6;7;9 | 10 |
24 | 84 | M | OS | HM | CF3m | 2 | 12 | 11 | 2 |
25 | 88 | M | OD | HM | CF5m | 2 | 17 | 1 | 4 |
26 | 55 | F | OD | 20/200 | 20/140 | 1 | 3 | – | 12 |
27 | 68 | F | OS | CF1m | 20/80 | 2 | 9 | 9 | 6 |